Scientists find potential new use for cancer drug in gene therapy for blood disorders

Bruce Torbett, PhD, is an associate professor at The Scripps Research Institute. Credit: Photo courtesy of The Scripps Research Institute.

Scientists working to make gene therapy a reality have solved a major hurdle: how to bypass a blood stem cell's natural defenses and efficiently insert disease-fighting genes into the cell's genome.

In a new study led by Associate Professor Bruce Torbett at The Scripps Research Institute (TSRI), a team of researchers report that the drug rapamycin, which is commonly used to slow cancer growth and prevent organ rejection, enables delivery of a therapeutic dose of genes to blood while preserving stem cell function.

These findings, published recently online ahead of print by the journal Blood, could lead to more effective and affordable long-term treatments for blood cell disorders in which mutations in the DNA cause abnormal cell functions, such as in leukemia and sickle cell anemia.

Improving Gene Delivery to Blood Stem Cells

Viruses infect the body by inserting their own genetic material into . In gene therapy, however, scientists have developed "gutted" viruses, such as the human immunodeficiency virus (HIV), to produce what are called "." Viral vectors carry therapeutic genes into cells without causing viral disease. Torbett and other scientists have shown that HIV vectors can deliver genes to .

For a disease such as leukemia or leukodystrophy, where mutations in the DNA cause abnormal cell function, efficiently targeting the stem cells that produce these blood cells could be a successful approach to halting the disease and prompting the body to produce healthy blood cells.

"If you produce a genetic modification in your blood stem cells when you are five years old, these changes are lifelong," said Torbett. Furthermore, the gene-modified stem cells can develop into many types of cells that travel throughout the body to provide therapeutic effects.

However, because cells have adapted defense mechanisms to overcome disease-causing viruses, engineered viral vectors can be prevented from efficiently delivering genes. Torbett said that when scientists extract blood stem cells from the body for gene therapy, HIV viral vectors are usually able to deliver genes to only 30 to 40 percent of them. For leukemia, leukodystrophy or genetic diseases where treatment requires a reasonable number of coming from stem cells, this number may be too low for therapeutic purposes.

This limitation prompted Torbett and his team, including TSRI graduate student Cathy Wang, the first author of the study, to test whether rapamycin could improve delivery of a gene to blood stem cells. Rapamycin was selected for evaluation based on its ability to control virus entry and slow cell growth.

The researchers began by isolating stem cells from cord blood samples. They exposed the blood stem cells to rapamycin and HIV vectors engineered to deliver a gene for a green florescent protein, which causes cells to glow. This fluorescence provided a visual marker that helped the researchers track gene delivery.

The researchers saw a big difference in both mouse and human stem cells treated with rapamycin, where therapeutic genes were inserted into up to 80 percent of cells. This property had never been connected to rapamycin before.

Helping Blood Stem Cells Survive

The researchers also found that rapamycin can keep stem cells from differentiating as quickly when taken out of the body for gene therapy. This is important because scientists need time to work on extracted blood stem cells—yet once these cells leave the body, they begin to differentiate if manipulated into other types of and lose the ability to remain as stem cells and pass on therapeutic genes.

"We wanted to make sure the conditions we will use preserve stem cells, so if we transplant them back into our animal models, they act just like the original stem cells," said Torbett. "We showed that in two sets of animal models, stem cells remain and produce gene-modified cells."

The researchers hope these methods could someday be useful in the clinic. "Our methods could reduce costs and the amount of preparation that goes into modifying blood stem cells using viral vector gene therapy," said Wang. "It would make accessible to a lot more patients."

She said the next steps are to carry out preclinical studies using rapamycin with stem cells in other animal models and then see if the method is safe and effective in humans. The team is also working to delineate the dual pathways of rapamycin's method of action in blood stem cells.

More information: The study can be accessed at bloodjournal.hematologylibrary… blood-2013-12-546218

add to favorites email to friend print save as pdf

Related Stories

Scientists use stem cells to create HIV resistance

Jun 10, 2014

(Medical Xpress)—Yuet Wai Kan of the University of California, San Francisco and colleagues have created HIV-resistant white blood cells by editing the genomes of induced pluripotent stem cells. The researchers ...

One cell's meat is another cell's poison

May 30, 2014

As a new therapeutic approach, Janus kinases are currently in the limelight of cancer research. The focus of interest is the protein JAK2. By inhibiting this protein one tries to cure chronic bone marrow ...

Immune cells regulate blood stem cells

Feb 21, 2014

Researchers in Bern, Germany, have discovered that, during a viral infection, immune cells control the blood stem cells in the bone marrow and therefore also the body's own defences. The findings could allow ...

Recommended for you

Human brain has coping mechanism for dehydration

12 hours ago

(HealthDay)—Although dehydration significantly reduces blood flow to the brain, researchers in England have found that the brain compensates by increasing the amount of oxygen it extracts from the blood. ...

User comments